Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

Autor: Marmé, Frederik, Harter, Philipp, Redondo, Andres, Reuss, Alexander, Ray-Coquard, Isabelle Laure, Lindemann, Kristina, Kurzeder, Christian, Van Nieuwenhuysen, Els, Bellier, Charlotte, Pietzner, Klaus, El-Balat, Ahmed, García-Duran, Carmen, Wimberger, Pauline, Perez-Fidalgo, Jose Alejandro, Selle, Frederic, de Gregorio, Nikolaus, Burges, Alexander, Romero, Ignacio, Hasenburg, Annette, Pautier, Patricia
Zdroj: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA5501-LBA5501, 83p
Databáze: Supplemental Index